NCT01581138View on ClinicalTrials.gov

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2013

Conditions
Chronic Hepatitis C Virus
Interventions
DRUG

VX-222

400 mg tablets twice daily for oral administration

DRUG

telaprevir

1125 mg tablets twice daily for oral administration

DRUG

ribavirin

1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily

Trial Locations (18)

Unknown

Birmingham

Anaheim

Riverside

San Diego

Englewood

Orlando

Marietta

Baltimore

New York

Asheville

Winston-Salem

Cincinnati

Pittsburgh

Germantown

Nashville

Austin

San Antonio

Norfolk

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01581138 - VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C | Biotech Hunter | Biotech Hunter